ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Inflammation Disrupts Memory - What Can You Do to Protect Your Brain?

Artificial sweeteners linked to risk of weight gain, heart disease and other health issues

All About Ginkgo Biloba: Benefits of This Timeless Herbal Supplement

Yarrow Oil: Here's Why It Deserves a Place in Your First-Aid Kit

Vitamin D supplement use associated with lower risk of breast cancer

Carnitine deficiency suggested as contributor to autism

Hop Oil: A Safe Sleep Aide

Lutein — An Important Nutrient for Eye and Brain Health

White Camphor Oil: The Purest Camphor Oil

Taurine: Facts About This Crucial Amino Acid

 
Print Page
Email Article

Cyberonics VNS Therapy May Improve Cognition in Alzheimer's Disease

  [ 68 votes ]   [ Discuss This Article ]
www.ProHealth.com • November 29, 2002


Data from a pilot study of Vagus Nerve Stimulation (VNS) Therapy treating Alzheimer's disease (AD) has been published in the November issue of the Journal of Clinical Psychiatry. The article, entitled "Cognition-Enhancing Effect of Vagus Nerve Stimulation in Patients with Alzheimer's disease: A Pilot Study" suggests that VNS Therapy may improve cognition in patients with AD.

In this study ten patients with mild to moderate AD were implanted with the VNS Therapy system and stimulated with left cervical (neck area) vagus nerve stimulation in the same way the treatment is currently delivered to treat patients with pharmacoresistant epilepsy. Response was defined as an improvement in or no worsening of AD symptoms based on the Alzheimer's disease Assessment Scale-cognitive (ADAS-cog). Patients with AD typically worsen nine points in the ADAS-cog each year.

After three months of VNS Therapy, seven of ten patients with AD responded to VNS Therapy according to the ADAS-cog. Of the seven responders, six had improvements in their cognitive symptoms of AD and one had no worsening. The median change on the ADAS-cog was a 3 point improvement. After six months of VNS Therapy, seven of the ten patients had improvements in symptoms compared with their baseline ADAS-cog assessments. The ten patients had a median improvement in the ADAS-cog of 2.5 points after six months of VNS Therapy. VNS Therapy was well tolerated in all of the patients involved in the study, and the side effects were mild and transient.

"The results of this pilot study demonstrate a positive effect of VNS Therapy on cognition in patients with Alzheimer's disease and merits further investigation in larger populations of Alzheimer's disease patients," said Magnus Sjogren, M.D., lead author of the article and Associate Professor at the department of Neuropsychiatry in Molndal, Sweden. "Of the seven patients showing improvement after six months with VNS Therapy, three were on concomitant cholinesterase inhibitors and four were not. The results also suggest that VNS Therapy may be a valuable and effective adjunctive therapy for patients already receiving drug therapy, as well as for those patients who do not tolerate cholinergic therapy."

The standard of care for treating the cognitive effects of AD is a class of drugs known as cholinesterase inhibitors. According to the Alzheimer's Association, about half of the people who receive cholinergic therapy experience a modest improvement in cognitive symptoms. Of the seven patients treated with VNS Therapy who showed improvements in cognitive symptoms at six months, three were receiving concomitant cholinesterase inhibitors and four were not. The patients receiving concomitant cholinesterase inhibitors during the study were taking those medications for at least one year prior to study entry. Importantly, the pilot results suggest that VNS Therapy may be beneficial in treating cognitive symptoms of AD with or without concomitant cholinergic therapy.



Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength Mitochondria Ignite™ with NT Factor® Ultra EPA  - Fish Oil


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Block Acid Reflux to Prevent Esophageal Problems! Block Acid Reflux to Prevent Esophageal Problems!
The Remarkable Benefits of Reishi Medicinal Mushrooms The Remarkable Benefits of Reishi Medicinal Mushrooms
Are You Obtaining the Proper Enzymes? Are You Obtaining the Proper Enzymes?
Strontium - The Missing Mineral for Strong Bones Strontium - The Missing Mineral for Strong Bones
Soothe, Heal and Regulate Your Digestive System with Nutrient-Rich Aloe Vera Soothe, Heal and Regulate Your Digestive System with Nutrient-Rich Aloe Vera

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map